Association between Macrophage Migration Inhibitory Factor Gene Variation and Response to Glucocorticoid Treatment in Sudden Sensorineural Hearing Loss

Audiol Neurootol. 2015;20(6):376-82. doi: 10.1159/000438741. Epub 2015 Oct 2.

Abstract

Several lines of evidence suggest the role of the immune system in the pathogenesis of sudden sensorineural hearing loss (SSNHL). Macrophage migration inhibitory factor (MIF) mediates its role in various immune and inflammatory conditions by the regulation of immune reactions. Several studies have confirmed an association between MIF gene polymorphisms and susceptibility to various inflammatory and autoimmune disorders. The aim of this study was to explore the association between the MIF (-173 G/C) polymorphism (rs755622) and SSNHL in an Iranian population. In this case-control association study, SSNHL cases (n = 77) were included. Normal healthy subjects (n = 100) were also recruited from the same region. Genotyping for MIF (-173 G/C) polymorphism was carried out using the polymerase chain reaction-restriction fragment length polymorphism technique. The frequency of the MIF -173 C allele carriers (GC + CC genotype) was significantly elevated in SSNHL patients who responded to glucocorticoid treatment compared with the patients with no response to treatment. These results suggest that the MIF gene polymorphism is associated with a response to glucocorticoid treatment in patients with SSNHL.

MeSH terms

  • Adult
  • Case-Control Studies
  • Dexamethasone / therapeutic use*
  • Female
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Genotype
  • Glucocorticoids / therapeutic use*
  • Hearing Loss, Sudden / drug therapy*
  • Hearing Loss, Sudden / genetics
  • Humans
  • Injection, Intratympanic
  • Intramolecular Oxidoreductases / genetics*
  • Iran
  • Macrophage Migration-Inhibitory Factors / genetics*
  • Male
  • Middle Aged
  • Pharmacogenetics
  • Polymerase Chain Reaction
  • Polymorphism, Restriction Fragment Length
  • Polymorphism, Single Nucleotide
  • Prednisone / therapeutic use*
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Macrophage Migration-Inhibitory Factors
  • Dexamethasone
  • Intramolecular Oxidoreductases
  • MIF protein, human
  • Prednisone